pharma
Pfizer to Halt Alzheimer’s and Parkinson’s Drug Research
Pfizer to Halt Alzheimer’s and Parkinson’s Drug Research
Jim Daley | Jan 7, 2018
The company’s recent effort to find new treatments for Alzheimer’s ended in disappointment.
Dengue Vaccine Program Halted Over Safety Issues
Dengue Vaccine Program Halted Over Safety Issues
Shawna Williams | Dec 5, 2017
The drug may worsen future infections for people who haven't already been exposed to the virus.
Clinical Trial Reporting for Pharma-Sponsored Trials Shows Improvement
Clinical Trial Reporting for Pharma-Sponsored Trials Shows Improvement
Diana Kwon | Dec 4, 2017
The Good Pharma Scorecard finds some big pharmaceutical companies are meeting legal standards for disclosing results—but many studies still go unreported.
Study: Hidden Conflicts of Interest Permeate Medicine
Study: Hidden Conflicts of Interest Permeate Medicine
Diana Kwon | Jan 18, 2017
Three investigations reveal the influence of industry money in patient advocacy groups, treatment guidelines, and Twitter feeds. 
Novartis Buys US Drugmaker for Up To $665 Million
Novartis Buys US Drugmaker for Up To $665 Million
Tracy Vence | Nov 22, 2016
The Swiss pharma giant is acquiring Oklahoma-based Selexys Pharmaceuticals, a maker of drugs for inflammatory and thrombotic diseases.
The Growth of Iowa Biotech
The Growth of Iowa Biotech
Jenny Rood | Jul 31, 2016
The state’s industry draws inspiration from medicine as well as agriculture.
$1.5 Billion Pharma Buyout for Leukemia Drug
$1.5 Billion Pharma Buyout for Leukemia Drug
Jef Akst | Jun 1, 2016
Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.
Shire Buys Rare Disease Drug Developer
Shire Buys Rare Disease Drug Developer
Tracy Vence | Nov 2, 2015
The Irish drugmaker is set to acquire the Massachusetts-based Dyax in a $5.9 billion deal.
Daraprim Alternative
Daraprim Alternative
Tracy Vence | Oct 22, 2015
A specialty pharmaceuticals company announces plans to produce a toxoplasmosis drug containing the same active ingredient as the pill at the center of an ongoing drug-pricing controversy.
Biotech Stocks Take a Hit
Biotech Stocks Take a Hit
Kerry Grens | Sep 30, 2015
Some say the biotech bubble has burst over concerns that drug prices are too high—and may soon be regulated.